Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity

Hyosun Han, Ritu Agarwal, Valerie Martel-Laferriere, Douglas T. Dieterich

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Antiretroviral-related hepatotoxicity occurs commonly in patients with human immunodeficiency virus (HIV). Liver injury ranges from unconjugated hyperbilirubinemia and nodular regenerative hyperplasia to lactic acidosis and toxic hepatitis. Effective antiretroviral therapy has changed coinfected patients' primary morbidities and mortality to chronic liver disease rather than complications from HIV. Treatment for hepatitis C virus (HCV) is strongly encouraged early in all coinfected patients. However, drug-drug interactions must be considered to ensure safe and tolerable use alone or in combination with antiretroviral therapies. The first-generation and newer HCV direct-acting antivirals are promising in coinfected patients, with minimal side effects and hepatotoxicity.

Original languageEnglish
Pages (from-to)657-670
Number of pages14
JournalClinics in Liver Disease
Issue number4
StatePublished - Nov 2013


  • ARV
  • Coinfection
  • DAAs
  • Drug-induced liver injury
  • HCV
  • HIV
  • Hepatotoxicity


Dive into the research topics of 'Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity'. Together they form a unique fingerprint.

Cite this